Dabrafenib in combination with trametinib for low-grade glioma and relapsed or refractory high-grade glioma, with BRAF V600E mutations

Published on 06 Feb 2026
Last Updated on 06 Feb 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Dabrafenib in combination with trametinib for the following indications:

  • treatment of paediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy; and

  • treatment of paediatric patients 1 year of age and older with high-grade glioma (HGG) with a BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.

in view of acceptable clinical effectiveness and safety, and an acceptable pricing proposal by the company.

Funding status

Dabrafenib 50 mg, 75 mg capsules, and 10 mg dispersible tablet, and trametinib 0.5 mg, 2 mg tablets, and 4.7 g powder for oral solution, are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 April 2026.

Clinical indications, subsidy class and MediShield Life claim limits for dabrafenib and trametinib are provided in the Annex.

Guidance_Dabrafenib in combination with trametinib for low-grade glioma and relapsed or refractory high-grade glioma, with BRAF V600E mutations (6 Feb 2026)